The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Open accessAbstract
Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000’s. The path to the commercialization of oncology drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development. The pace at which pharmaceutical companies have formed partnerships to use proprietary nanoparticle technologies has considerably accelerated. It is now recognized that by enhancing the efficacy and/or tolerability of new drug candidates, nanotechnology can meaningfully contribute to create differentiated products and improve clinical outcome. This review describes the lessons learned since the commercialization of the first-generation nanomedicines including DOXIL® and Abraxane®. It explores our current understanding of targeted and non-targeted nanoparticles that are under various stages of development, including BIND-014 and MM-398. It highlights the opportunities and challenges faced by nanomedicines in contemporary oncology, where personalized medicine is increasingly the mainstay of cancer therapy. We revisit the fundamental concepts of enhanced permeability and retention effect (EPR) and explore the mechanisms proposed to enhance preferential “retention” in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages. The overall objective of this review is to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Self-citationMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,772
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“Therefore, the approach is aimed towards increasing interactions between NPs and cell and enhancing internalization of drugs without altering the overall biodistribution [6, 145, 146].”
BackgroundSelf-citationStrategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Self-citation
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationClinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Self-citationPhotothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
Liu, Y., Bhattarai, P., Dai, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00618k · Cited by 2,904
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,168
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Nanomaterials for In Vivo Imaging
Smith, B. R., & Gambhir, S. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00073 · Cited by 1,075
Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence
Chinen, A. B., Guan, C. M., Ferrer, J. R., Barnaby, S. N., Merkel, T. J., & Mirkin, C. A. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00321 · Cited by 1,032
Xue, J., Zhao, Z., Zhang, L., Xue, L., Shen, S., Wen, Y., Wei, Z., Wang, L., Kong, L., Sun, H., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.54 · Cited by 959
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 944
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery
Shi, L., Zhang, J., Zhao, M., Tang, S., Cheng, X., Zhang, W., Li, W., Liu, X., Peng, H., & Wang, Q. (2021) · Nanoscale · doi:10.1039/d1nr02065j · Cited by 808
Insight into nanoparticle cellular uptake and intracellular targeting
Yameen, B., Choi, W. I., Vilos, C., Swami, A., Shi, J., & Farokhzad, O. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.038 · Cited by 787
Self-citationNanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization
Sanità, G., Carrese, B., & Lamberti, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587012 · Cited by 765
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer
Cao, H., Dan, Z., He, X., Zhang, Z., Yu, H., Yin, Q., & Li, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b03148 · Cited by 694
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Self-citationThe Impact of Nanoparticle Protein Corona on Cytotoxicity, Immunotoxicity and Target Drug Delivery
Corbo, C., Molinaro, R., Parodi, A., Toledano Furman, N. E., Salvatore, F., & Tasciotti, E. (2016) · Nanomedicine · doi:10.2217/nnm.15.188 · Cited by 692
Liu, G., Zou, J., Tang, Q., Yang, X., Zhang, Y., Zhang, Q., Huang, W., Chen, P., Shao, J., & Dong, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b13421 · Cited by 691
Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 677
Current trends and challenges in cancer management and therapy using designer nanomaterials
Navya, P. N., Kaphle, A., Srinivas, S. P., Bhargava, S. K., Rotello, V. M., & Daima, H. K. (2019) · Nano Convergence · doi:10.1186/s40580-019-0193-2 · Cited by 672
Enzyme-responsive nanomaterials for controlled drug delivery
Hu, Q., Katti, P. S., & Gu, Z. (2014) · Nanoscale · doi:10.1039/c4nr04249b · Cited by 668
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Quantum dots in biomedical applications
Wagner, A. M., Knipe, J. M., Orive, G., & Peppas, N. A. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.022 · Cited by 632
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
Metal‐Organic Framework Nanoparticles in Photodynamic Therapy: Current Status and Perspectives
Lismont, M., Dreesen, L., & Wuttke, S. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201606314 · Cited by 622
Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery
Habibi, N., Kamaly, N., Memic, A., & Shafiee, H. (2016) · Nano Today · doi:10.1016/j.nantod.2016.02.004 · Cited by 619
Self-citationManaging diabetes with nanomedicine: challenges and opportunities
Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G., & Langer, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4477 · Cited by 613
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Gold Nanoparticles in Cancer Treatment
Sztandera, K., Gorzkiewicz, M., & Klajnert-Maculewicz, B. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00810 · Cited by 607
Photodynamic Therapy—Current Limitations and Novel Approaches
Gunaydin, G., Gedik, M. E., & Ayan, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.691697 · Cited by 599
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.036 · Cited by 527
Phthalocyanines as medicinal photosensitizers: Developments in the last five years
Li, X., Zheng, B.-D., Peng, X.-H., Li, S.-Z., Ying, J.-W., Zhao, Y., Huang, J.-D., & Yoon, J. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.08.003 · Cited by 523
Moradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Nanotechnology in cancer diagnosis: progress, challenges and opportunities
Zhang, Y., Li, M., Gao, X., Chen, Y., & Liu, T. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0833-3 · Cited by 510
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review
Riaz, M., Riaz, M., Zhang, X., Lin, C., Wong, K., Chen, X., Zhang, G., Lu, A., & Yang, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010195 · Cited by 509
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
A Perspective on Polylactic Acid-Based Polymers Use for Nanoparticles Synthesis and Applications
Casalini, T., Rossi, F., Castrovinci, A., & Perale, G. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00259 · Cited by 500
Zhu, J.-Y., Zheng, D.-W., Zhang, M.-K., Yu, W.-Y., Qiu, W.-X., Hu, J.-J., Feng, J., & Zhang, X.-Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02786 · Cited by 498
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
Grossen, P., Witzigmann, D., Sieber, S., & Huwyler, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.028 · Cited by 496
Jeyaraj, M., Gurunathan, S., Qasim, M., Kang, M.-H., & Kim, J.-H. (2019) · Nanomaterials · doi:10.3390/nano9121719 · Cited by 481
A holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Conde, J., Oliva, N., Zhang, Y., & Artzi, N. (2016) · Nature Materials · doi:10.1038/nmat4707 · Cited by 449
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Self-citationAn, F.-F., & Zhang, X.-H. (2017) · Theranostics · doi:10.7150/thno.19365 · Cited by 436
Advancing porphyrin's biomedical utility via supramolecular chemistry
Rajora, M. A., Lou, J. W. H., & Zheng, G. (2017) · Chem. Soc. Rev. · doi:10.1039/c7cs00525c · Cited by 427
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Polysaccharide-based nanoparticles for theranostic nanomedicine
Swierczewska, M., Han, H. S., Kim, K., Park, J. H., & Lee, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.015 · Cited by 415
Cloaking nanoparticles with protein corona shield for targeted drug delivery.
Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., et al. (2018) · Nature communications · doi:10.1038/s41467-018-06979-4 · Cited by 409
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Development of High‐Drug‐Loading Nanoparticles
Liu, Y., Yang, G., Jin, S., Xu, L., & Zhao, C. (2020) · ChemPlusChem · doi:10.1002/cplu.202000496 · Cited by 410
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
Self-citationBiomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
Soetaert, F., Korangath, P., Serantes, D., Fiering, S., & Ivkov, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.025 · Cited by 406
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3193 · Cited by 393
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
Rengan, A. K., Bukhari, A. B., Pradhan, A., Malhotra, R., Banerjee, R., Srivastava, R., & De, A. (2015) · Nano Letters · doi:10.1021/nl5045378 · Cited by 388
(2020) · IntechOpen eBooks · doi:10.5772/intechopen.87879 · Cited by 384
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration
Zhou, Z., Liu, X., Zhu, D., Wang, Y., Zhang, Z., Zhou, X., Qiu, N., Chen, X., & Shen, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.021 · Cited by 379
Wei, T., Chen, C., Liu, J., Liu, C., Posocco, P., Liu, X., Cheng, Q., Huo, S., Liang, Z., Fermeglia, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418494112 · Cited by 370
Multifunctional nanocrystals for cancer therapy: a potential nanocarrier
Joseph, E., & Singhvi, G. (2019) · Nanomaterials for Drug Delivery and Therapy · doi:10.1016/b978-0-12-816505-8.00007-2 · Cited by 367
Raza, A., Rasheed, T., Nabeel, F., Hayat, U., Bilal, M., & Iqbal, H. M. N. (2019) · Molecules · doi:10.3390/molecules24061117 · Cited by 367
Recent advances of controlled drug delivery using microfluidic platforms
Sanjay, S. T., Zhou, W., Dou, M., Tavakoli, H., Ma, L., Xu, F., & Li, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.013 · Cited by 365
Nanomedicine in the management of microbial infection – Overview and perspectives
Zhu, X., Radovic-Moreno, A. F., Wu, J., Langer, R., & Shi, J. (2014) · Nano Today · doi:10.1016/j.nantod.2014.06.003 · Cited by 362
Self-citationCancer‐Associated, Stimuli‐Driven, Turn on Theranostics for Multimodality Imaging and Therapy
Li, X., Kim, J., Yoon, J., & Chen, X. (2017) · Advanced Materials · doi:10.1002/adma.201606857 · Cited by 362
Fredman, G., Kamaly, N., Spolitu, S., Milton, J., Ghorpade, D., Chiasson, R., Kuriakose, G., Perretti, M., Farokhzad, O., & Tabas, I. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1065 · Cited by 357
Self-citationScintillating Nanoparticles as Energy Mediators for Enhanced Photodynamic Therapy
Kamkaew, A., Chen, F., Zhan, Y., Majewski, R. L., & Cai, W. (2016) · ACS Nano · doi:10.1021/acsnano.6b01401 · Cited by 355
Prodrug-based nanoparticulate drug delivery strategies for cancer therapy
Luo, C., Sun, J., Sun, B., & He, Z. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.008 · Cited by 352
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Marques, A. C., Costa, P. J., Velho, S., & Amaral, M. H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.035 · Cited by 349
Miller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Kohler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 347
Self-citationApplication of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs
Bayón-Cordero, L., Alkorta, I., & Arana, L. (2019) · Nanomaterials · doi:10.3390/nano9030474 · Cited by 344
Nanoparticles for drug delivery to the anterior segment of the eye
Janagam, D. R., Wu, L., & Lowe, T. L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.001 · Cited by 341
Islam, M. A., Xu, Y., Tao, W., Ubellacker, J. M., Lim, M., Aum, D., Lee, G. Y., Zhou, K., Zope, H., Yu, M., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0284-0 · Cited by 339
Self-citationDi Corato, R., Béalle, G., Kolosnjaj-Tabi, J., Espinosa, A., Clément, O., Silva, A. K. A., Ménager, C., & Wilhelm, C. (2015) · ACS Nano · doi:10.1021/nn506949t · Cited by 339
Advanced optoacoustic methods for multiscale imaging of in vivo dynamics
Deán-Ben, X. L., Gottschalk, S., Mc Larney, B., Shoham, S., & Razansky, D. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00765a · Cited by 337
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 333
Towards clinically translatable in vivo nanodiagnostics
Park, S.-M., Aalipour, A., Vermesh, O., Yu, J. H., & Gambhir, S. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.14 · Cited by 327
Colloidal capsules: nano- and microcapsules with colloidal particle shells
Bollhorst, T., Rezwan, K., & Maas, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00632a · Cited by 324
Evolution of macromolecular complexity in drug delivery systems
Kakkar, A., Traverso, G., Farokhzad, O. C., Weissleder, R., & Langer, R. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0063 · Cited by 320
Self-citationChoi, K. Y., Han, H. S., Lee, E. S., Shin, J. M., Almquist, B. D., Lee, D. S., & Park, J. H. (2019) · Advanced Materials · doi:10.1002/adma.201803549 · Cited by 319
Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy
Sun, B., Luo, C., Zhang, X., Guo, M., Sun, M., Yu, H., Chen, Q., Yang, W., Wang, M., Zuo, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11193-x · Cited by 319
Assessment of PEG on polymeric particles surface, a key step in drug carrier translation
Rabanel, J.-M., Hildgen, P., & Banquy, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.017 · Cited by 318
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles
Li, J., Ai, Y., Wang, L., Bu, P., Sharkey, C. C., Wu, Q., Wun, B., Roy, S., Shen, X., & King, M. R. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.046 · Cited by 313
Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
Buck, J., Grossen, P., Cullis, P. R., Huwyler, J., & Witzigmann, D. (2019) · ACS Nano · doi:10.1021/acsnano.8b07858 · Cited by 312
Metadata
- Authors
- Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 66
- Pages
- 2-25
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2153771870
- Cited by
- 2,824
- References
- 302
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.